Precision BioSciences, Inc.

NasdaqCM:DTIL 주식 리포트

시가총액: US$187.6m

Precision BioSciences 향후 성장

Future 기준 점검 2/6

Precision BioSciences 의 수익은 연간 3.9% 감소할 것으로 예상되는 반면, 연간 수익은 21.6% 로 증가할 것으로 예상됩니다. EPS는 연간 11.2% 만큼 성장할 것으로 예상됩니다.

핵심 정보

-3.9%

이익 성장률

11.19%

EPS 성장률

Biotechs 이익 성장25.2%
매출 성장률21.6%
향후 자기자본이익률n/a
애널리스트 커버리지

Low

마지막 업데이트06 May 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • May 13

Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Dec 29

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Summary Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming for a functional HBV cure superior to downstream competitors. Recent $75M capital raise extends DTIL's cash runway through major readouts, supporting continued clinical development and operational flexibility. Risks include potential safety events, competitive efficacy, and uncertain milestone/royalty revenue from partnered programs. Read the full article on Seeking Alpha
분석 기사 • Aug 06

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Celebrations may be in order for Precision BioSciences, Inc. ( NASDAQ:DTIL ) shareholders, with the analysts delivering...
분석 기사 • Jun 23

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision BioSciences, Inc. ( NASDAQ:DTIL ) shares have had a horrible month, losing 29% after a relatively good period...
분석 기사 • Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Dec 08

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Sep 02

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences promoted Cindy Atwell to chief business officer and carried out other leadership changes. Atwell, who was serving as senior vice president of Business Development and Alliance Management, will continue to oversee the Business Development and Alliance functions with added responsibility for Project and Portfolio Management, the company said in a Sept. 2 press release. Jeff Smith, co-founder and formerly chief technology officer, was promoted to chief research officer and will assume responsibility for the management and direction of the company’s research programs and report directly to the CEO Michael Amoroso. Precision added that Derek Jantz, co-founder and chief scientific officer, will step down from the board to focus his time partnering with Amoroso in making company strategy and managing relationships with external stakeholders. Jantz departure would reduces the number of management members serving on the board, the company added. DTIL +1.27% to $1.60 premarket Sept. 1
Seeking Alpha • Aug 16

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

PBCAR0191 is being explored in a phase 1/2 study in patients with relapsed/refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia. Data updates from PBCAR0191, PBCAR19B for non-Hodgkin's Lymphoma and PBCAR269A for multiple myeloma are expected before end of 2022. Precision has established several partners for use of its ARCUS in vivo gene editing platform; these partners are Eli Lilly, Novartis and iEcure. Company has enough cash to fund its operations until the end of 2024, giving plenty of cash runway for the foreseeable future. Precision BioSciences, Inc. (DTIL) is a great speculative biotech play to look into. That's because it is advancing an allogeneic CAR-T pipeline, along with an in vivo gene editing pipeline. Speaking of its CAR-T treatments, the main one in the pipeline would be PBCAR0191, which is being explored in a phase 1/2 study in patients with relapsed/refractory (r/r) Non-Hodgkin Lymphoma ((NHL)) and r/r B-cell Acute Lymphoblastic Leukemia. In the most recent interim update, it noted that relapsed patients given this CAR T were able to achieve a 100% response rate. Why I believe it may have some potential upside is because Precision expects to release updated results from this very same study before the end of 2022. In addition, it has a pretty solid pipeline when it comes to in vivo gene editing as well. It has several wholly owned treatments and then it has many others which have already been partnered with a few pharmaceutical companies. With proof of concept established using PBCAR0191 for the treatment of patients with relapsed/refractory NHL B-cell ALL, plus an update on data from the phase 1/2 study expected before the end of 2022, these are the reasons why I believe that Precision Biosciences is a great speculative biotech play to look into. PBCAR0191 For Treatment Of Patients With Non-Hodgkin's Lymphoma And B-Cell Acute Lymphoblastic Leukemia The main program to go over involves the use of PBCAR0191, which is being developed for the treatment of patients with non-Hodgkin's lymphoma ((NHL)) and B-Cell Acute Lymphoblastic Leukemia (B-ALL). Lymphoma is cancer that develops in the lymphatic system, which is the body's fighting immune system network. The lymphatic system is composed of: Lymph Nodes, spleen, thymus gland and bone marrow area. This type of cancer affects these organs and several others. There are two main types of lymphomas that you are likely aware of, which are: Hodgkin's Lymphoma Non-Hodgkin's Lymphoma These are the two main ones, although there are some other types. Both of these types are lymphomas that have problems with the B-cells in the body, which are responsible for fighting off infections in a person's body. The main difference is found under a microscope where each of the cells are shown to be different. This is not the only difference between Hodgkin's and Non-Hodgkin's lymphoma. Hodgkin's Lymphoma is a rare type of lymphoma and only about 8,500 cases diagnosed in 2016. This compares to Non-Hodgkin's Lymphoma which had 72,500 cases were diagnosed in 2016 and is the seventh most diagnosed type of cancer. In addition, there is a difference in 5-year survival rates, which are shown directly below: Hodgkin's Lymphoma - More than 86% of patients diagnosed with this type of cancer survive 5 years or more Non-Hodgkin's Lymphoma - More than 70% of patients diagnosed with this type of cancer survive 5 years or more The main thing is that a majority of biotechs targeting the large non-Hodgkin's lymphoma market. That's because the global Non-Hodgkin's Lymphoma market is expected to reach $12.5 billion by 2027. This is a very large market opportunity for Precision Biosciences. The use of PBCAR0191 is being explored in an ongoing phase 1/2a study, which demonstrated that it could achieve high response rates in patients who relapsed after CAR T. This trial is an open-label, dose-escalation and dose expansion study to evaluate safety and efficacy of PBCAR0191 in patients with relapsed/refractory (r/r) Non-Hodgkin Lymphoma ((NHL)) and r/r B-cell Acute Lymphoblastic Leukemia. Speaking of dose level and dose expansions, it is expected that Precision Biosciences could reach up to 6 dose levels total. What I will show below is that the biotech was able to achieve high response rates in a very sick patient population. How sick? Well consider that these are CAR T relapsed patients who received on average 5 prior lines of treatments. That means they gone through and failed multiple types of treatments, along with other CAR T, before entering this particular study. The positive results released as an update in June of 2022 layout the most recent dose levels which were used for this study. These dose levels used for PBCAR0191 were dose level 3 (DL3) with enhanced lymphodepletion (treatment to kill existing T-cells to make room for new ones) in 6 patients and then dose level 4 (DL4b) with reduced/decreasing lymphodepletion in another 6 patients (This dose level is referred to as the "New Cohort" or latest cohort as of January 2022). As of the May 31, 2022 cutoff date, the breakdown for each dose level cohort noted directly above is as follows: It noted that 11 out of 11 (100%) of patients achieved an objective response rate (ORR) It was said that 8 out of 11 patients achieved a complete response rate 6 patients from the pool of 11 patients remain with an ongoing response for 18 months + The data for which I highlighted above deals with both dose level cohorts (DL3 and DL4b). However, what I find intriguing is that the dose level 4b cohort (new cohort), had shown to be superior over dose level 3. This was even achieved with a reduction of lymphodepletion as well, which is always good for safety in the end. This is good news for Precision Biosciences, because it is targeting a huge unmet need. These are patients with aggressive lymphomas who fail on autologous CAR Ts and other therapies. There is no approved standard of care ((SOC)) for these patients and their progression-free survival for the time being is a mere 2 months. As far as a catalyst goes, there will be an update on the use of PBCAR0191 for the treatment of patients with relapsed/refractory NHL towards the end of 2022. In addition, to updates on the other CAR Ts in the pipeline which are PBCAR19B and PBCAR269A, which are being developed for the treatment of patients with NHL and Multiple Myeloma ((MM)) respectively. It will likely be an update on data and maybe even plans for the next study. The biotech intends to meet with the FDA to discuss the data observed and then see what it needs to do next to advance it. The hope is that it can continue to reduce the amount of lymphodepletion patients need with treating their aggressive lymphomas. This could both improve safety and efficacy of PBCAR0191. Two Massive Partnerships Worth Billions Of Dollars In Potential Milestone Payments The thing is that Precision Biosciences uses its ARCUS gene editing technology for its pipeline. It remains to be seen how well it does when it is actually utilized in humans, however, it has already attracted the attention of several pharmaceutical companies. One of the most recent partnerships for licensing the ARCUS in vivo gene editing technology involves Novartis (NVS). Novartis wanted to enter this deal to get its hands on the ARCUS gene editing technology. Precision Biosciences received an upfront payment of $75 million. That's a good start to help fund its operations, but the real deal happens if it can meet all of its milestones and earn up to $1.4 billion in cash. Of course, should any product reach the market it will obtain the usual tiered royalties on sales. Its main job will be to develop a single ARCUS nuclease that is safe and efficient for In Vivo gene insertion. The goal is to attempt to develop cures for large markets like sickle cell disease and beta thalassemia. The thalassemia market is expected to reach $3.53 billion in 2022. On the other hand, the other market opportunity is much larger. It is expected that the sickle-cell disease market will reach $5.5 billion in 2023. These are the initial indications for which Novartis wants to happen. I believe that an in vivo ARCUS nuclease will be developed. The test is whether or not such a product is efficient when it delivered to humans in a phase 1 study. These indications are just the start of what is possible. That's because the partnership could eventually expand to other hemoglobinopathies that exist out there.

이익 및 매출 성장 예측

NasdaqCM:DTIL - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/202814-86-49-684
12/31/202717-82-35-523
12/31/202621-66-31-463
3/31/202645-44-59-59N/A
12/31/202534-47-67-66N/A
9/30/20251-84-74-73N/A
6/30/20251-78-64-64N/A
3/31/202551-22-59-59N/A
12/31/2024697-59-58N/A
9/30/20247511-48-48N/A
6/30/20248816-66-65N/A
3/31/202458-20-73-72N/A
12/31/202349-43-86-84N/A
9/30/202352-49-100-98N/A
6/30/202347-31-49-45N/A
3/31/202331-59-52-48N/A
12/31/202225-73-49-46N/A
9/30/202221-76-52-48N/A
6/30/202238-93-105-101N/A
3/31/2022102-40-113-108N/A
12/31/2021116-31-17-11N/A
9/30/2021118-32-6-1N/A
6/30/2021101-47-41N/A
3/31/202134-10127N/A
12/31/202024-109-92-87N/A
9/30/202022-106-104-94N/A
6/30/202019-101-101-86N/A
3/31/202024-88-98-77N/A
12/31/201922-93N/A-71N/A
9/30/201921-87N/A-63N/A
6/30/201918-76N/A-64N/A
3/31/201915-69N/A-57N/A
12/31/201811-46N/A-52N/A
9/30/20187-38N/A-46N/A
12/31/20176-21N/A-24N/A
12/31/20167-8N/A92N/A

애널리스트 향후 성장 전망

수입 대 저축률: DTIL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: DTIL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: DTIL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: DTIL 의 수익(연간 21.6%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: DTIL 의 수익(연간 21.6%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: DTIL의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/18 08:39
종가2026/05/15 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Precision BioSciences, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Debjit ChattopadhyayGuggenheim Securities, LLC
Debjit ChattopadhyayH.C. Wainwright & Co.
Patrick TrucchioH.C. Wainwright & Co.